Clinical Trials
16
Active:0
Completed:1
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:9
Phase 2:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (56.3%)Not Applicable
5 (31.3%)Early Phase 1
1 (6.3%)Phase 2
1 (6.3%)Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
Not Applicable
Recruiting
- Conditions
- Relapsed/Refractory B-cell Lymphoma
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07097207
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Other (Non U.S.), China
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Early Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Biological: TCR-T Cells Injection
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06904859
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06644443
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Astragalus + Gemcitabine
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06234072
- Locations
- 🇨🇳
Shenzhen University General Hospital, Shenzhen, Guangdong, China
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
Not Applicable
Recruiting
- Conditions
- T Lymphoblastic Leukemia/Lymphoma
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Shenzhen University General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05620680
- Locations
- 🇨🇳
Li Yu, Shenzhen, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found